Capmatinib in MET exon 14-mutated non-small-cell lung cancer: final results from the open-label, phase 2 GEOMETRY mono-1 trial. Wolf J, Hochmair M, Han JY, Reguart N, et al. Lancet Oncol 2024;25:1357-1370.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Wolf J, Hochmair M, Han JY, Reguart N, et al. Capmatinib in MET exon 14-mutated non-small-cell lung cancer: final results from the open-label, phase 2 GEOMETRY mono-1 trial. Lancet Oncol 2024;25:1357-1370.
PMID: 39362249